Investigation of the Effect of Maras Powder (Nicotıana Rustica Linn) Use on Insulin Resistance

Abstract

Project Number

There is no project number

Investigation of the Effect of Maras Powder (Nicotiana Rustica Linn) Use on Insulin Resistance

Abstract

Objective: Maras powder (MP), a type of smokless tobacco, it draws attention due to the lack of sufficient studies on its health effects. This study was conducted for the first time and aimed to determine the effect of MP use on insulin resistance. Material and Methods: 58 men, 25 MP users and 33 control groups were included in the study. For the study, 5 ml of venous blood was collected from the subjects and serum glucose(mg/dL), total cholesterol(mg/dL), triglycerides(mg/dL), and HDL(mg/dL) were measured via Cobas 6000 series c 501 clinical Biochemistry analyzer. Homeostasis Model Assesment-Insulin Resistance (HOMA-IR) method was used to evaluate insulin resistance. Results: According to the statistical analysis, triglyceride, glucose, insulin and HOMA-IR levels were significantly higher in MP users compared to the control group (p<0.05). In addition, significant correlations were observed between insulin, HOMA-IR, glucose and triglyceride levels in MP users. Conclusion: In this study, we obtained data indicating that the use of MP with limited information regarding its health effects, may be associated with insulin resistance. This study was conducted for the first time and we believe it will address the existing gap in the literature in this area of research and enhance the public awareness.

Keywords

• Insulin resistance
• Maras Powder
• Tobacco
• HOMA-IR

Project Number

There is no project number

Ethical Statement

The study was approved by the ethics committee of the Kahramanmaras Sutcu Imam University (date: 14.06.2017; approval number: 4

References

1. Le Foll B, Piper ME, Fowler CD et al. Tobacco and nicotine use. Nat Rev Dis Primers 2022;8:19.
2. Terefe B, Jembere MM, Chekole B. et al. Frequency of cigarette smoking and its associated factors among men in East Africa: a pooled prevalence analysis of national survey using multinomial regression. BMC Public Health 2024;24:668.
3. Köksal N, İnanç F, Kılınç M. Sigara ve dumansız tütün (Maraş otu) kullananlarda serum adenozin deaminaz düzeyleri. Tıp Araştırmaları Dergisi 2004;2:7-11.
4. Sierro N, Battery JND, Bovet L et al. The impact of genome evolution on the allotetraploid Nicotiana rustica an intriguing stroy of enhanced alkaloid production BMC Genomics 2018; 19:855.
5. Carlsson S, Midthjell K, Grill V. Smoking is associated with an increased risk of type 2 diabetes but a decreased risk of autoimmune diabetes in adults: an 11-year follow-up of incidence of diabetes in the Nord-Trondelag study. Diabetologia 2004;47:1953-6.
6. Özbayer C, Yağcı E, Kurt H. Obezite, Tip 2 Diyabet ve İnsülin Direnci Arasındaki Bağlantı: İnflamasyon. Tıp Fakültesi Klinikleri Dergisi 2018; 1(2):27-36.
7. Narayan KMV, Zhang P, Kanaya AM, et al. Diabetes: The Pandemic and Potential Solutions. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2006. Chapter 30. Available from: https://www.ncbi.nlm.nih.gov/books/NBK11777/ Co-published by Oxford University Press, New York.
8. Sun H, Saeedi P, Karuranga S, Pinkepank M, et al. Erratum to "IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045" [Diabetes Res. Clin. Pract. 2022; 183:109119]. Diabetes Res Clin Pract 2023;204:110945.

9. Freeman AM, Acevedo LA, Pennings N. Insulin Resistance. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507839/
10. Durlach V, Vergès B, Al-Salameh A, Bahougne T, et al. Smoking and diabetes interplay: A comprehensive review and joint statement. Diabetes Metab 2022;48(6):101370.
11. Bergman BC, Perreault L, Hunerdosse D, Kerege A, et al. Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes 2012;61(12):3156-66.
12. National Center for Biotecholohy Information. [Accessed Date:22/09/2024].Available from: https://www.ncbi.nlm.nih.gov/pmc/?term=Nicotina+rustica
13. Boffetta P, Hecht S, Gray N, Gupta P, et al. Smokeless tobacco and cancer. Lancet Oncol 2008;9:667-75.
14. Weitkunat R, Sanders E, Lee PN. Meta-analysis of the relation between European and American smokeless tobacco and oral cancer. BMC Public Health 2007;7:334.
15. Hoffmann D, Djordjevic MV. Chemical composition and carcinogenicity of smokeless tobacco. Adv Dent Res 1997;11:322-9.
16. Organization WH, Tobacco. Key facts. [Accessed date:28.09.2024]. Avaliable from: https://www.who.int/health-topics/tobacco#tab=tab_1.
17. Tanriverdi, G. Dumansız Tütün Maraş Otunun Sağlığa Zararları: Geleneksel Derleme. Halk Sağlığı Hemşireliği Dergisi.2022;4(3):284-292.
18. Cok I, Ozturk R. Urinary cotinine levels of smokeless tobacco (Maras powder) users. Human Exp Toxicol 2000;19:650-655.
19. Guven A, Tolun F. Effects of Smokeless Tobacco “Maras Powder” Use on Nitric Oxide and Cardiovascular Risk Parameters. Int J Med Sci 2012;9(9):786-792.
20. Keten HS, Olmez S, Ucer H, Isık O, et al. Acute effects of Maras powder (smokeless tobacco) on blood pressure and heart rate. Cukurova Med J 2017;42(2):210-215.
21. Kurtul N, Çıl MY, Paçacı SD. Serum total sialic acid levels in smokers and users of smokeless tobacco in from of oral powder (Maras powder). J Biomed Sci 2005;12:559-63.
22. Kılınç M, Okur E, Yıldırım I, Inanç F, et al. The investigation of the effect of Maras powder (smokeless tobacco) on hematological parameters. Turk J Haematol 2004; 21:131-6.
23. Kannel WB. Update on the role of cigarette smo-king in coronary artery disease. Am Heart J 1981;101:319–28.
24. Kong C, Nimmo L, Elatrozy T, Anyaoku V, et al. Smoking is associated with increased hepatic lipase activity, insülin resistance, dyslipidemia and early atherosclerosis in type 2 diabetes. Atherosclerosis 2001;156:373–378.
25. Laws A, Reaven GM. Evidence for an indepen-dent relationship between insülin resistance and fasting plasma HDL cholesterol, triglyceride and insulin concentrations. J Intern Med 1992;231:25–30.
26. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, et al. Insulin resistance and cigarette smoking. Lancet 1992;339:1128 –30.
27. Li Z, Xu W, Su Y, Gao K, et al. Nicotine induces insulin resistance via downregulation of Nrf2 in cardiomyocyte. Mol Cell Endocrinol 2019; 15(495):110507.
28. Onat A, Hergenç G, Türkmen S, Yazıcı M, et al. Discordance between Insulin resistance and metabolic syndrome: features and associated cardiovascular risk in adults with normal glucose regulation. Metabolism 2006;55:445-52.
29. Craig WY, Palomaki GR, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentra-tions: an analysis of published data. BMJ 1989;298:784–8.
30. Jeppesen J, Hein OH, Suadicani DD, Gyntelberg F. Low triglycerides–high-density lipoprotein choles-terol and risk of ischemic heart disease. Arch Intern Med 2001;161:361-416.